257 related articles for article (PubMed ID: 34730001)
1. Medication adherence among patients with advanced prostate cancer using oral therapies.
Pilon D; LaMori J; Rossi C; Durkin M; Ghelerter I; Ke X; Lafeuille MH; Ellis L; Lefebvre P
Future Oncol; 2022 Jan; 18(2):231-243. PubMed ID: 34730001
[TBL] [Abstract][Full Text] [Related]
2. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
[TBL] [Abstract][Full Text] [Related]
3. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
Schultz NM; Flanders SC; Wilson S; Brown BA; Song Y; Yang H; Lechpammer S; Kassabian V
Adv Ther; 2018 Oct; 35(10):1639-1655. PubMed ID: 30191463
[TBL] [Abstract][Full Text] [Related]
4. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
5. Prescribing Patterns of Oral Antineoplastic Therapies Observed in the Treatment of Patients With Advanced Prostate Cancer Between 2012 and 2014: Results of an Oncology EMR Analysis.
Malangone-Monaco E; Foley K; Varker H; Wilson KL; McKenzie S; Ellis L
Clin Ther; 2016 Aug; 38(8):1817-24. PubMed ID: 27491282
[TBL] [Abstract][Full Text] [Related]
6. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
Thiery-Vuillemin A; Poulsen MH; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Lefresne F; Lukac M; Van Sanden S; Pissart G; Reid A;
Eur Urol; 2020 Mar; 77(3):380-387. PubMed ID: 31594705
[TBL] [Abstract][Full Text] [Related]
7. Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.
Lu-Yao G; Nikita N; Keith SW; Nightingale G; Gandhi K; Hegarty SE; Rebbeck TR; Chapman A; Kantoff PW; Cullen J; Gomella L; Kelly WK
Eur Urol; 2020 Feb; 77(2):158-166. PubMed ID: 31420248
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan.
Okumura H; Inoue S; Naidoo S; Holmstrom S; Akaza H
Jpn J Clin Oncol; 2021 Aug; 51(8):1319-1329. PubMed ID: 34037235
[TBL] [Abstract][Full Text] [Related]
9. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
Pilon D; Queener M; Lefebvre P; Ellis LA
J Med Econ; 2016 Aug; 19(8):777-84. PubMed ID: 27031255
[TBL] [Abstract][Full Text] [Related]
10. A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide.
Woon DTS; Finelli A; Cheung DC; Martin LJ; Alibhai S; Wallis CJD; Diong C; Saskin R; Kulkarni G; Fleshner N
Urology; 2021 Jul; 153():147-155. PubMed ID: 33592224
[TBL] [Abstract][Full Text] [Related]
11. A drug safety evaluation of enzalutamide to treat advanced prostate cancer.
Saad F; Hamilou Z; Lattouf JB
Expert Opin Drug Saf; 2021 Jul; 20(7):741-749. PubMed ID: 34114527
[TBL] [Abstract][Full Text] [Related]
12. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
13. Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer.
Alibhai SMH; Breunis H; Feng G; Timilshina N; Hansen A; Warde P; Gregg R; Joshua A; Fleshner N; Tomlinson G; Emmenegger U
JAMA Netw Open; 2021 Jul; 4(7):e2114694. PubMed ID: 34213559
[TBL] [Abstract][Full Text] [Related]
14. Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer.
Demirci A; Bilir C; Gülbağcı B; Hacıbekiroğlu İ; Bayoğlu İV; Bilgetekin İ; Koca S; Çınkır HY; Akdeniz N; Gül D; Varım C; Demirci U; Öksüzoğlu B
Sci Rep; 2021 Jul; 11(1):14131. PubMed ID: 34239026
[TBL] [Abstract][Full Text] [Related]
15. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Kim SI; Szeto AH; Morgan KP; Brower B; Dunn MW; Khandani AH; Godley PA; Rose TL; Basch EM; Milowsky MI; Whang YE; Crona DJ
PLoS One; 2021; 16(6):e0253021. PubMed ID: 34153052
[TBL] [Abstract][Full Text] [Related]
16. Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis.
Roumiguié M; Paoletti X; Neuzillet Y; Mathieu R; Vincendeau S; Kleinclauss F; Mejean A; Guy L; Timsit MO; Lebret T
Future Oncol; 2021 May; 17(14):1811-1823. PubMed ID: 33543650
[No Abstract] [Full Text] [Related]
17. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
[TBL] [Abstract][Full Text] [Related]
18. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
[TBL] [Abstract][Full Text] [Related]
19. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Massoudi M; Balk M; Yang H; Bui CN; Pandya BJ; Guo J; Song Y; Wu EQ; Brown B; Barlev A; Flanders S
J Med Econ; 2017 Feb; 20(2):121-128. PubMed ID: 27570999
[TBL] [Abstract][Full Text] [Related]
20. Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer.
Freedland SJ; Li S; Pilon D; Bhak RH; Narkhede S; Lefebvre P; Young-Xu Y
Curr Med Res Opin; 2021 Apr; 37(4):635-642. PubMed ID: 33571020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
